No-Spa Forte (Drotaverine Hydrochloride)

Drotaverine blocks phosphodiesterase enzymes, which raises intracellular cyclic AMP levels. The increased cAMP reduces calcium entry into smooth‑muscle cells, leading to muscle relaxation and a decrease in spasm across the gastrointestinal, biliary, uterine and urinary systems.

The appropriate dose of No-Spa Forte is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and overall health. Patients should follow the exact regimen provided by their doctor and not adjust the dose on their own.

Safety data for drotaverine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified prescriber after a thorough assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as papaverine, drotaverine has a more selective phosphodiesterase‑inhibiting profile, which often results in fewer anticholinergic side effects. Its onset of action is rapid, and it is generally well tolerated, making it a preferred choice for many clinicians treating smooth‑muscle spasm.

Store No-Spa Forte at ambient temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

No-Spa Forte is taken orally with a glass of water. It may be taken with or without food, but patients should follow the specific instructions given by their prescriber regarding timing and any dietary considerations.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, cardiac arrhythmias, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience any signs of these conditions.

No-Spa Forte should be avoided in individuals with known hypersensitivity to drotaverine or any excipients, in patients with severe cardiovascular instability, and in those taking contraindicated medications such as strong CYP3A4 inhibitors or other phosphodiesterase inhibitors, unless a prescriber decides the benefits outweigh the risks.